Sonnet BioTherapeutics Holdings, Inc. (SONN)
Market Cap | 15.95M |
Revenue (ttm) | 708,745 |
Net Income (ttm) | -27.48M |
Shares Out | 60.59M |
EPS (ttm) | -0.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 316,806 |
Open | 0.256 |
Previous Close | 0.262 |
Day's Range | 0.256 - 0.267 |
52-Week Range | 0.240 - 2.070 |
Beta | 0.36 |
Analysts | Buy |
Price Target | 2.30 (+773.9%) |
Earnings Date | May 16, 2022 |
About SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-0... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for SONN stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 773.86% from the latest price.
News

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, SON-1210, and SON-1410 p...
Trending Penny Stocks to Buy This Month? 3 to Watch in April
Can these penny stocks continue to climb this month? The post Trending Penny Stocks to Buy This Month?

Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has b...

Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American As...
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from pre...

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate
The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ: SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonn...

Trading Penny Stocks? Top Stock Market News for March 16th, 2022
What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Represents Sonnet's first IND cleared Phase 1 trial initiation expected in 2Q22 PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Compan...

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study initiation ...

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drug...

Top Penny Stocks to Buy This Week? 3 You Need to Watch
With October off to a great start for penny stocks, which small-caps are you watching? The post Top Penny Stocks to Buy This Week?

Penny Stocks That Will Explode? Check These 3 Out For Your List
Check these three penny stocks out for your September watchlist The post Penny Stocks That Will Explode? Check These 3 Out For Your List appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September
Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?

See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 rep...

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset...

Sonnet BioTherapeutics Stock Slumps After $30M Equity Raise
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) priced the underwritten public offering of 35.3 million shares (including pre-funded warrants) and warrants to purchase up to 35.3 million shares. Eac...

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...

Buying Penny Stocks Right Now? 3 to Watch in 2021
Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now?

SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today
Sonnet BioTherapeutics (SONN) stock is taking off on Thursday and investors can thank retail traders on social media for pumping it higher. The post SONN Stock: The Social Media Buzz Sending Sonnet Bio ...

What's Happening With Sonnet BioTherapeutics Stock?
Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. No company-specific reports are driving up the stock price today, so it appears th...

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio Completed $15.9 million At-The-Market Financing SON-1010 and...

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targ...

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics H...

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE / May 17,...